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The mouse arylamine N-acetyltransferase 2 (Nat2) and its homologue (NAT1) in humans are known to detoxify xenobiotic arylam-
ines and are also thought to play a role in endogenous metabolism. Human NAT1 is highly over-expressed in estrogen receptor positive
breast tumours and is implicated in susceptibility to neural tube defects. In vitro assays have suggested an endogenous role for human
NAT1 in folate metabolism, but in vivo evidence to support this hypothesis has been lacking. Mouse Nat2 provides a good model to
study human NAT1 as it shows similar expression proﬁles and substrate speciﬁcities. We have generated transgenic mice lacking a func-
tional Nat2 gene and compared the urinary levels of acetylated folate metabolite para-aminobenzoylglutamate in Nat2 knockout and
Nat2 wild-type mice. These results support an in vivo role for mouse Nat2/human NAT1 in folate metabolism. In addition, eﬀects of
the Nat2 deletion on sex ratios and neural tube development are described.
 2007 Elsevier Inc.
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Open access under CC BY license.ArylamineN-acetyltransferases have well-deﬁned roles in
detoxiﬁcation of xenobiotic arylamines and hydrazines.
There are two NAT genes in humans, showing distinct sub-
strate speciﬁcities [1] and expression proﬁles [2], with human
NAT2 expressedmainly in the liver and intestine, and widely
held to have a role in xenobiotic metabolism. HumanNAT1
and its homologue in mouse (mouse Nat2) is strongly
expressed in the placenta, early in embryonic development
[3] in the developing neural tube [4] and in folate-sensitive
cells contributing to the neuroendocrine system [5], as well
as in the adult, in erythrocytes and a range of epithelia [2,6].
Both human NAT1 and human NAT2 genes are poly-
morphic and there are suggestions that the polymorphic
status may inﬂuence susceptibility to cancers in epithelia
exposed to xenobiotic toxins [7]. Recent studies linking lev-0006-291X 2007 Elsevier Inc.
doi:10.1016/j.bbrc.2007.10.026
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Open access under CC BY license.els of NAT1 expression with those of the estrogen receptor
in breast tumour tissue [8] indicate that the role of NAT1 in
carcinogenesis and tumour growth in some tissues relates
to endogenous as opposed to xenobiotic metabolism. In
vitro studies have shown that human NAT1 is able to acet-
ylate the folate catabolite para-aminobenzoylglutamate
(pABAglu) [9,10], however, to date, there has been no con-
ﬁrmation of this activity in vivo. We have used a well-char-
acterized transgenic mouse model to address the
relationship in vivo between human NAT1/mouse Nat2
and folate metabolism, and describe phenotypic eﬀects of
deleting the mouse Nat2 gene in mice.
Methods
Nat2 transgenic mouse maintenance and breeding
All work involving animals was carried out according to the UK
Animals (Scientiﬁc Procedures) Act of 1986 under license from the UK
Home Oﬃce.
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insertion of a lacZ-containing cassette, has been described [11]. The
Nat2*null allele was bred from a129/Ola background onto two diﬀerent
genetic backgrounds (A/J and C57Bl/6, supplied by Harlan, UK) by
backcrossing over ten generations. Nat2/, Nat2+/ and Nat2+/+ animals
used for analysis were generated by intercrossing, (mating Nat2+/ male
and Nat2+/ females). On weaning, oﬀspring were sexed on the basis of
the external morphology of the genitalia. Ear biopsies were taken for
genotyping and sexing and DNA isolated using Sigma GenElute mam-
malian genomic DNA miniprep kit. Oﬀspring sex was conﬁrmed by
screening for the Sry gene using Sry and MyoG primers and PCR con-
ditions detailed in [12]. Primers used for Nat2 genotyping were as follows:
Neo-T (forward, 5 0CATCGCCTTCTATCGCCTTCT3 0) and mNat2-910
(reverse, 5 0TTCCAAGTACATGGAAGGACACC30) were used to detect
the Nat2*null allele, with mNat2-1 (forward) 5 0ATGGACATCGAAGC
GTACTTTG3 0, and mNat2-910 (reverse) used to detect the wild-type
Nat2 allele as described [11]. Genotypic and phenotypic data pertaining to
each animal were stored and analyzed using Microsoft Access databases.
Adult (8- to 10-week-old) male C57Bl/6 Nat2+/+ and Nat2/ mice
(n = 8 animals per genotype) were used for urine analysis in two inde-
pendent experiments. All mice were fed on standard mouse chow given
ad libitum. Animals given dietary folate supplement were fed ad libitum on
mash made up with folic acid (20 lM, pH adjusted to pH 7.0) added to
standard mouse chow at 20 mg folic acid/kg dry chow [13] over four to ﬁve
days. Urine samples were collected during routine cage transfer on days 3–
5 and samples from four animals per genotype were pooled for analysis.
To obtain embryos, timed matings were established, with noon on the
day of the vaginal plug designated as embryonic day 0.5 (e0.5). Pregnant
dams were killed by cervical dislocation. Embryos were dissected from theFig. 1. ES-MS and -MS/MS analysis of authentic acetyl-pABAglu. (A) Negati
of m/z 307.06. Inset; chemical structure of the [M-H] ion of acetyl-pABAglu
authentic acetyl-pABAglu. (C) Negative ion ES-MS spectrum of urine from Na
H] ion (m/z 307) from urine of Nat2+/+ mice given dietary folate supplemenuterus into ice-cold 10 mM Potassium phosphate pH 7.5, 145 mM NaCl
(phosphate buﬀered saline) containing 4% paraformaldehyde.
Mass spectroscopy
Mouse urine analysis by mass spectroscopy. Urine samples (200 ll)
were diluted 1:1 with ammonium hydroxide solution (40 ll of concen-
trated ammonium hydroxide in 1 ml water, pH 10) and centrifuged at
8000g for 10 min. The supernatant (400 ll) was applied to an anion-
exchange cartridge (Oasis MAX, Waters, UK) previously washed with
1 ml of methanol and conditioned with 1 ml of water prior to sample
application. Analytes were eluted from the cartridge with 5% ammonium
hydroxide in water, followed by 1 ml of methanol and ﬁnally 1 ml of 5%
formic acid in methanol.
All fractions were analysed by both negative- and positive-ion elec-
trospray (ES) mass spectrometry (MS) and tandem mass spectrometry
(MS/MS) on a Q-TOF Global (Waters, UK) instrument. The instrument
was operated in the ‘‘V-mode’’ at a resolution of 7500 (FWHM). MS/
MS spectra were recorded on selected precursor ions using a collision-
energy of 20 eV.Results and discussion
Metabolic eﬀect of deleting mouse Nat2
The ability of adult Nat2+/+ and Nat2/ mice to acet-
ylate the folate catabolite para-aminobenzoylglutamateve ion ES-MS spectrum of authentic acetyl-pABAglu, giving a [M-H] ion
showing exact mass. (B) MS/MS of the ion of [M-H] ion (m/z 307) from
t2+/+ mice given dietary folate supplement. (D) MS/MS of the ion of [M-
t. See Table 1 for interpretation of fragment ions.
Table 2
Analysis of sex and genotype in A/J intercross oﬀspring
Nat2 genotype Oﬀspring numbers
Males (Predicted) Females
+/+ 50 (55) 77
+/ 77 (110) 122
/ 62 (55) 55
v2 p < 0.01a p < 0.01a
Inheritance of the Nat2null allele was determined in oﬀspring of intercross
mating using PCR. Numbers of oﬀspring predicted assuming independent
segregation and Mendelian inheritance of Nat2 (located on chromosome
8) and Sry gene (located on Y chromosome) are given in parentheses.
a Signiﬁcant deviation from predicted values.
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urine samples. Negative-ion ES-MS analysis of puriﬁed
acetylated pABAglu gave a [M-H] ion at m/z 307.06
(theoretical m/z 307.09). This compound eluted in the
formic acid fraction from the anion-exchange column.
The ion of m/z 307.06 was also found in ES-MS spectra
of the formic acid anion-exchange fraction from the urine
of Nat2+/+ mice given a dietary folate supplement, indi-
cating that acetyl-pABAglu is present in their urine
(Fig. 1). However, this ion was absent from the ES-MS
spectra of all anion-exchange fractions from Nat2/
mouse urine. To conﬁrm the identity of components hav-
ing a mass of 307.06 in Nat2+/+ mouse urine, the ion at
m/z 307 found in the formic acid fraction from the
anion-exchange column was further analysed by MS/
MS, and the resultant spectrum compared to that of
the [M-H] ion of puriﬁed acetyl-pABAglu (Fig. 1, Table
1). The MS/MS spectra obtained from the ion of m/z 307
in urine of the Nat2+/+ mice were essentially identical to
that of standard acetyl-pABAglu, however the corre-
sponding spectra from Nat2/ mice urine did not corre-
spond to the acetyl-pABAglu standard (Table 1). These
data indicate that acetyl-pABAglu is present in the urine
of Nat2+/+ mice given dietary folate supplements, but
undetectable in urine from Nat2/ mice.
Early work on human NAT1 enzyme demonstrated
that the acetylation of NAT1-speciﬁc substrate para-
aminobenzoic acid by NAT1 in human erythrocyte cyto-
sols is inhibited in vitro by folic acid, and folate levels in
these cells appears to show an inverse correlation with
acetylation activity [14]. Subsequently, recombinant
human NAT1 enzyme was shown to acetylate the folate
catabolite pABAglu [9,10]. The role of folate in cancer
biology is complex, with folate supplements used to pre-
vent tumour formation in normal tissues, although these
supplements may accelerate the growth of established
tumours, and antifolate agents have some eﬃcacy as can-
cer treatments [15,16]. This duality shown by folate mir-
rors the eﬀects of human NAT1 on cell growth. High
level of expression of human NAT1 has been shown to
enhance cell growth under certain conditions [17], but is
associated with improved clinical outcome in ER positive
breast cancer [8].Table 1
MS/MS analysis of the ion of m/z 307 in the formic acid fraction from the an
MS/MS Fragment
ion m/z
Proposed fragment ion
elemental formula
Authentic
acetyl-pABAglu
134.06 C8H8NO +
178.04 C9H8NO3 +
219.09 C12H15N2O2 +
245.07 C13H13N2O3 +
263.07 C13H15N2O4 +
a Urine samples collected from adult male mice given a dietary supplement o
of m/z 307 further analysed by MS/MS.
b For both authentic acetyl-pABAglu and Nat2+/+ derived samples, peak int
, peak absent. Experimental m/z values agree (<±0.03 Da) with theoretical mNat2 deletion aﬀects oﬀspring sex ratios in A/J strain
Nat2/ mice are described as overtly aphenotypic [11].
However, on an A/J genetic background, within homozy-
gous null litters there is a gender bias with a 1.5 fold excess
of males (89 males; 59 females) that diﬀers signiﬁcantly from
the predicted 1:1 ratio (p = 0.01) suggesting that homozy-
gosity of the Nat2null allele may be deleterious to females,
or beneﬁcial in males. A reversed gender bias is seen in oﬀ-
spring from intercross matings (Nat2+/ M · Nat2+/ F),
in which both parents are heterozygous (Table 2), with a
ratio of males to females of 0.7:1 (184 males to 254 females
p = 0.001). In these intercross litters, the female excess is
made up of Nat2+/+ and Nat2+/ animals (Table 2), again
suggesting that in females, the wild-type allele has selective
advantage. Together these results indicate that mutations
at the Nat2 locus have a gender-dependent eﬀect on oﬀ-
spring survival. By screening for the Sry gene [12], we have
conﬁrmed that the skewed sex ratios do not result from sex
reversal. (Supplementary Figure S1).Eﬀect of Nat2 deletion on neural tube closure
We have tested whether Nat2 genotype inﬂuences sus-
ceptibility to neural tube defects, using the C57Bl/6 strain,
which is not prone to neural tube defects, and scoring
embryos for neural tube defects at e10.5 and e11.5.
Amongst Nat2/ oﬀspring derived by incrossing, out of
64 embryos examined, only one embryo was observed toion-exchange column from urine of Nat2+/+ and Nat2/ mice
Urinary 307.06 peaka Acetyl-pABAGlu
peak intensitiesb
Nat2+/+
peak intensitiesbNat2+/+ Nat2/
+  1.0 1.0
+  0.66 0.65
+  0.29 0.25
+  0.18 0.18
+  0.30 0.25
f folic acid were fractionated by anion-exchange chromatography and ions
ensities are expressed relative to the peak of mass 134.06. +, peak present;
/z values given in the Table.
Fig. 2. Wholemount views of embryos showing neural tube defects. Embryos derived by crossing C57Bl/6 Nat2+/+ and Nat2/ mice, and harvested at
e10.5–e11.5. (A) Normal embryo (e11.5) viewed from right hand side. (B) Embryo (e11.5) with neural tube defect, showing incomplete closure of the
anterior neuropore, viewed from right hand side in main panel; inset, dorsal view. (C) Embryo (e10.5) with neural tube defect at cervical level, viewed from
right in main panel; inset, dorsal view. Arrowheads point to regions of incomplete closure of the neural tube. The orientation of the embryos is indicated in
dorsal views; C, caudal; R, rostral.
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imbalance in parental Nat2 phenotype, crosses were set
up using Nat2+/+ and Nat2/ parents, generating
Nat2+/ oﬀspring. The incidence of neural tube defects
amongst Nat2+/ oﬀspring derived in this way was 14%
(4/28). In three out of the four cases described in here, asso-
ciated with the Nat2 null allele, the position of the defect is
caudal to the hindbrain, at the cervical level (Fig. 2).
An allelic association between the orthologous human
NAT1 and orofacial clefting has been recorded [18] and a
link between NAT1 imbalance and developmental defects
has been described for the human NAT1 alleles with
respect to the incidence of spina biﬁda [19]. In this human
study, natural variants with little acetylating activity were
found to have a protective eﬀect amongst oﬀspring, and
both maternal and oﬀspring genotypes aﬀected the out-
come. Gender bias towards females amongst exencephalic
embryos both in mice and in men is well documented, for
review [20]. The A/J strain is known to be susceptible to
neural tube defects, and it is possible that the male bias
seen amongst A/J Nat2/ oﬀspring is due to developmen-
tal abnormalities and lower survival rates amongst female
embryos, although the numbers presented here are too
small at present for statistical analysis.
Folate supplements have been used widely to prevent
neural tube defects and to reduce the risk of colon cancer,
reviewed in [15]. The data presented here indicate that
deleting mouse Nat2 reduces the acetylation of the folate
catabolite pABAglu. Our results suggest that the complex
relationship between human NAT1 polymorphism and epi-
thelial cancers [7] including breast cancer [8,17], and the
inﬂuence of NAT1 genotype on neural tube defects [19]
may result from a functional link in vivo between NAT1
acetylation activity and folate metabolism.Acknowlegments
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